Figure 1
From: Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies
Combine morphologic and fluorescence in situ hybridization analysis with LSI D20S108 probe ( × 100 objective) in two patients without therapy-related myeloid neoplasm. No morphological dysplasia was noted in myeloid or erythroid lineages. Del(20q) was detected in myeloid and erythroid lineages (red arrows), but not in lymphocytes or plasma cells (green arrows). (a and c) Bone marrow with involvement of plasma cell myeloma; (b and d) Bone marrow with involvement of chronic lymphocytic leukemia. (a and b) Bone marrow smear stained with Wright-Giemsa; (c and d) fluorescence in situ hybridization analysis with probe of D20S108.
